
FDA Approves Bristol Myers Squibb’s COBENFY™ for Schizophrenia Treatment
Bristol Myers Squibb (NYSE: BMY) has announced FDA approval of COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults. COBENFY is the first new class of…












